# **Special Issue**

# The Discovery of Novel Antitumor Drugs

### Message from the Guest Editor

The aim of the Special Issue is to attract high-quality papers focused on the activity and molecular mechanisms of action of novel antitumor molecules. We are especially interested in articles that seek to discover novel oncological targets based on biologic and genotypic contexts and further rationally design effective molecules to illustrate the relationship between chemical structure and biological activity. The potential anticancer inhibitors for the Special Issue include, but are not limited to, traditional chemotherapeutic agents, targeted therapies, and immunomodulators. Small molecules, antibody-drug conjugates, PROTACs, peptides, and polysaccharides are all eligible for the Special Issue. We welcome both original and review articles.

### **Guest Editor**

Dr. Peiju Qiu

School of Medicine and Pharmacy, Ocean University of China, 5 Yushan Road, Qingdao 266003, China

### Deadline for manuscript submissions

closed (30 April 2025)



## **Molecules**

an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.6 Indexed in PubMed



mdpi.com/si/202423

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

mdpi.com/journal/molecules





# **Molecules**

an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.6 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

### **Editor-in-Chief**

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

#### **Author Benefits**

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

#### Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

## **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).

